Michael F Sugrue

Title: Michael F. Sugrue: Innovator in Pharmaceutical Advancements

Introduction

Michael F. Sugrue is a notable inventor based in Blue Bell, Pennsylvania, with a significant contribution to the field of pharmaceuticals. He holds five patents that reflect his innovative approach to medical treatments and drug formulations. His work primarily focuses on methods that enhance the administration of pharmaceutical compounds.

Latest Patents

Among his latest patents, Sugrue has developed methods for administering integrin receptor antagonists. This invention provides a convenient means for systemically administering an integrin receptor antagonist or a pharmaceutically effective amount thereof to a patient by introducing the antagonist, in an ophthalmic formulation, to the patient's eye. Another significant patent involves muscarine antagonists, which concerns novel 1,3-dihydro-1-[(1-heteroarylpiperidin-4-yl)piperidin-4-yl]-2H-benzimidazoles and their derivatives. These compounds are endowed with antimuscarinic activity and are useful in the treatment and/or prevention of myopia, commonly known as nearsightedness.

Career Highlights

Sugrue is currently associated with Merck & Company, Inc., a leading global healthcare company. His role at Merck allows him to contribute to the development of innovative pharmaceutical solutions that address various medical needs.

Collaborations

Throughout his career, Sugrue has collaborated with esteemed colleagues, including Pierre J. Mallorga and Richard W. Ransom. These collaborations have further enriched his research and development efforts in the pharmaceutical industry.

Conclusion

Michael F. Sugrue's contributions to pharmaceutical innovations demonstrate his commitment to improving patient care through advanced medical treatments. His patents reflect a deep understanding of drug formulation and administration, positioning him as a key figure in the field.